Clinical studies with dexfenfluramine: from past to future.
d Fenfluramine (dF) (15 mg twice daily) has been studied in controlled trials in human obesity. It has been shown to increase adherence to weight lowering programs, to double the number of patients losing 10 kg or more when compared with a fairly efficient placebo plus dietary counselling, and to prevent weight regain when continued over a 1 year period. Weight loss after 1 month and 4 months is likely to predict subsequent outcome. Also, significant improvement in metabolic risk factors and blood pressure were clearly demonstrated, even more markedly in some obesity-associated diseases, when body weight is maintained at a lower level. Even moderate but sustained weight loss of some 10% of starting weight or less has been confirmed to be of medical value. Tolerance and safety of dF can be considered acceptable, even if longer term follow-up is clearly needed. These studies support the concept that long-term pharmacotherapy with this serotoninergic drug might help achieve better outcome in the management of many obese patients, particularly in preventing relapse. The long-term managerial strategies to be developed for each patient might thus include dF together with dietary advice, behavioral modification and physical exercise, either simultaneously or sequentially.
Guy-Grand
B
B
Service de Médecine et Nutrition, Hôtel-Dieu, Paris, France.
D001067:Appetite Depressants / Q000627:therapeutic use*; D005277:Fenfluramine / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D015431:Weight Loss
D001067:Appetite Depressants; D005277:Fenfluramine